Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug for inflammatory bowel disease

A technology for inflammatory bowel disease, medicine, applied in the field of medicine for inflammatory bowel disease

Inactive Publication Date: 2013-01-09
SUMITOMO DAINIPPON PHARMA CO LTD
View PDF9 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the current situation of drug therapy, not only after the interruption of the drug administration, but also during the drug administration, IBD relapse is observed in a certain proportion of patients, and in many cases, its mode of treatment as a symptom is only aimed at the inhibition of inflammatory factors. secretion and action

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug for inflammatory bowel disease
  • Drug for inflammatory bowel disease
  • Drug for inflammatory bowel disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0125] Single dose in mouse model of colitis induced with dextran sulfate (DSS) aqueous solution Relapse suppression effect of administration of anti-CD81 antibody

[0126] An aqueous solution of dextran sulfate (DSS) was administered to mice to induce relapsing-remitting ulcerative colitis. Anti-CD81 antibody was administered once to this relapsing-remitting ulcerative colitis mouse model, and it was combined with a single dose of anti-TNF-α antibody and multiple doses of sulfasalazine (both existing treatments). The inhibitory effect of anti-CD81 antibody administered in a single dose on the relapse (reoccurrence) of ulcerative colitis was examined in comparison with a single dose.

[0127] 1. Method

[0128] (1) Preparation of DSS

[0129] Dextran sulfate (product of TdB consultancy AB, average molecular weight 47,000) was dissolved in drinking water to prepare a 1% aqueous solution.

[0130] (2) Preparation of application solution

[0131] For the test drugs ...

Embodiment 2

[0155] Anti-CD81 antibody in mouse model of colitis induced by 2,4,6-trinitrobenzenesulfonic acid (TNBS) long-term remission in

[0156] The anti-CD81 antibody was once administered to a mouse model of relapsing-remitting inflammatory bowel disease (crohn's disease and ulcerative colitis) by administering TNBS to Mice were obtained, and the relapse (recurrence)-inhibitory effect of single-dose administration of anti-CD81 antibody on inflammatory bowel disease was examined by comparison with multiple-dose administration of sulfasalazine, an existing therapeutic drug.

[0157] 1 method

[0158] (1) Preparation of TNP-OVA

[0159] Mix 0.5g ovalbumin (OVA: Sigma) and 0.5g K 2 CO 3 (Nacalai Tesque, Inc.) was dissolved in 25 ml of distilled water for injection (OVA solution). Dissolve 0.5 g of 2,4,6-trinitrobenzenesulfonic acid (TNBS: Nacalai Tesque, Inc.) in 25 ml of 0.1 M K 2 CO 3 Medium (TNBS solution). The OVA solution and TNBS solution were mixed and stirred over...

Embodiment 3

[0173] In the colitis mouse model induced by dextran sulfate (DSS) aqueous solution, a single dose of Relapse Inhibitory Effect of Anti-CD81 Antibody

[0174] Anti-CD81 antibody was administered once to a mouse model of relapsing-remitting ulcerative colitis obtained by administering dextran sulfate (DSS) aqueous solution to mice, and the effect of anti-CD81 antibody on longer-term induction was examined. Relapse inhibition in relapsing-remitting ulcerative colitis.

[0175] 1. Method

[0176] (1) Preparation of DSS

[0177] Dextran sulfate (product of Wako Pure Chemical Industries, Ltd., average molecular weight 5,000) was dissolved in drinking water to prepare a 2% aqueous solution.

[0178] (2) Preparation of application solution

[0179] For the test drug under study, hamster anti-CD81 antibody was used, and for the pathological condition control test drug, hamster IgG was used. A concentrated stock solution of hamster anti-CD81 antibody (clone: ​​2F7, product ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Anti-CD81 antibody displays not only a remission induction effect, but also a long-term remission maintenance effect on inflammatory bowel disease when administered in a single dose, and is therefore effective as a drug for maintaining remission from inflammatory bowel disease. Moreover, anti-CD81 antibody is effective as a drug for the prevention, amelioration and treatment of inflammatory bowel disease because it has preventive, therapeutic and ameliorating effects on refractory inflammatory bowel disease.

Description

technical field [0001] The present invention relates to a drug for maintaining remission of inflammatory bowel disease (hereinafter may be abbreviated as "IBD") containing an anti-CD81 antibody as an active ingredient or a drug for refractory inflammatory bowel disease containing an anti-CD81 antibody as an active ingredient Preventive, ameliorative or therapeutic drugs. The present invention also relates to a method of using an anti-CD81 antibody for maintaining remission of inflammatory bowel disease or a method of using an anti-CD81 antibody for preventing, improving or treating refractory inflammatory bowel disease. technical background [0002] The intestine is an organ that digests and absorbs nutrients and water necessary for the vital activities of a living body. Meanwhile, the intestine also has an immune defense function to remove foreign substances such as pathogens, and thus, it also serves as an organ in charge of life support by controlling opposite properties...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P1/00A61P1/04
CPCA61K2039/545C07K16/2896A61K2039/505A61P1/00A61P1/04
Inventor 渡边孝正
Owner SUMITOMO DAINIPPON PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com